

New Hope To Outsmart Lung Cancer

AI & Genomics
Advances

That Make Lung Cancer
Screening Convenient and
Effective With a Single Blood Draw



Introducing SPOT-MAS Lung

A smart blood-based test for
routine lung cancer screening
by applying AI to check DNA
from lung cells.

90%

Sensitivity⁽¹⁾

92%

Specificity⁽¹⁾


(1) Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Enhance Lung Cancer Detection (January 11, 2025). [dx.doi.org/10.2139/ssrn.5094108](https://doi.org/10.2139/ssrn.5094108)

What is SPOT-MAS Lung test?



SPOT-MAS Lung is a cancer screening blood test that integrates multiple AI techniques to analyze circulating tumor DNA (ctDNA) derived from lung cells. This methodology offers a precise, non-invasive, and affordable test specifically designed for lung cancer screening⁽¹⁾.

(1) Nguyen, Van Thien Chi et al. Cost-Effective Shallow Genome-Wide Sequencing for Profiling Plasma cfDNA Signatures to Enhance Lung Cancer Detection (January 11, 2025). [dx.doi.org/10.2139/ssrn.5094108](https://doi.org/10.2139/ssrn.5094108)



Who is SPOT-MAS Lung for?

This screening test is intended for adults aged 50 years and older, particularly those at elevated risk for cancer.⁽²⁾⁽³⁾⁽⁴⁾⁽⁵⁾

- Smoking history ≥ 20 pack-years or quit smoking < 15 years ago
- Exposure to secondhand smoke, radon, air pollution, or occupational/environmental
- First-degree relatives with lung cancer
- Diagnosed with lung disease: COPD, pulmonary fibrosis
- Exposure to carcinogens: arsenic, asbestos, beryllium, cadmium, chromium, coal smoke, diesel exhaust, nickel, silica, soot, and uranium
- Suspected symptoms (Persistent cough ≥ 3 weeks...)
- Lung lesions of unclear nature OR classified as benign/possibly benign



(2) U.S. Preventive Services Task Force Recommendation for Lung Cancer Screening. (3) The Japan Lung Cancer Society: Lung Cancer Screening Guidelines (4) Infante, M. V., & Cardillo, G. (2020). European Respiratory Journal (5) Kerpel-Fronius et al. (2021). Journal of Thoracic Oncology

Patient story⁽⁶⁾

Jane is a non-smoking 54-year-old woman with a family history of lung cancer. During a routine check-up, Jane's doctor recommended SPOT-MAS test.

The test results were alarming; they indicated potential circulating tumor DNA (ctDNA) signal from Lung cells. She then underwent a chest CT scan, which revealed a 2.2 cm lesion in her lung. Jane was referred to a specialized oncology hospital, where a PET-CT scan confirmed the presence of a suspicious lung lesion.

Acting quickly, her medical team performed surgery to remove the affected part of her lung. The surgery was a success, and the pathology report confirmed that Jane had stage IIB bronchial adenocarcinoma, a type of lung cancer.

Thanks to the early detection through the SPOT-MAS test, Jane's cancer was caught at a stage where it could be effectively treated.

(6) Dang Nguyen, L. H. et al (2024). A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study. Future Science OA, 10(1). <https://doi.org/10.1080/20565623.2024.2395244>

SPOT-MAS portfolio	Scope	AI Technology
SPOT-MAS 10 ^(*)	Multiple features of 10 cancer types: Breast, Lung, Liver-Biliary tract, Colorectum, Stomach, Ovary, Pancreas, Esophagus, Endometrium, Head & Neck	Multi AI machine learning and deep learning models
SPOT-MAS Lung	Multiple lung-specific features	Cell-free Multiomic ATLAS
SPOT-MAS CRC	Multiple colorectum-specific features	

(*) First multi-cancer early detection test to complete clinical validation in Asia on

9024 participants

**Speak to your
Healthcare
Professional
today about
SPOT-MAS!**

Gene Solutions Genomics Pte Ltd

📍 Tower C, Tai Seng Exchange 5 Tai Seng Avenue, #02-54 Singapore 536671

✉ infosg@genesolutions.com 🌐 www.genesolutions.com

Scan here to learn more about lung cancer risk and the SPOT-MAS test.

